Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
In brief, in English
This funding opportunity supports clinical trials evaluating the efficacy and safety of products to address unmet needs in rare diseases or conditions. Eligible applicant types are not specified in the text.
Written by a model from the publisher's text. The official page is the authority. How data is produced
The purpose of this opportunity is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.
Change history
First seen 28 Sept 2026, last checked 22 Nov 2026. 1 recorded version.
- 28 Sept 2026 · 2e38ead6e7e6